Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT01662505 Completed - Clinical trials for Leukemia, Myeloid, Acute

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Start date: August 2012
Phase: Phase 1
Study type: Interventional

To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML

NCT ID: NCT01660906 Completed - Clinical trials for Chronic Phase Chronic Myeloid Leukemia

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Start date: December 2012
Phase: Phase 4
Study type: Interventional

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

NCT ID: NCT01660607 Completed - Clinical trials for Acute Myeloid Leukemia

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Start date: December 2011
Phase: Phase 1/Phase 2
Study type: Interventional

For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with a T cell depleted graft, the infusion of naturally occurring regulatory T cells with conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and improving immune reconstitution.

NCT ID: NCT01659255 Completed - Clinical trials for Chronic Lymphocytic Leukaemia

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Start date: August 17, 2012
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

NCT ID: NCT01659047 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control

NCT ID: NCT01659021 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Start date: December 4, 2012
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

NCT ID: NCT01658319 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Start date: May 2011
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies. Drugs used in chemotherapy, such as methoxyamine and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with fludarabine phosphate may kill more cancer cells.

NCT ID: NCT01658007 Terminated - Clinical trials for Recurrent Adult Lymphoblastic Lymphoma

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

SIR-MO-1101
Start date: August 2012
Phase: Early Phase 1
Study type: Interventional

The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other cancer drugs that are often given to patients with relapsed leukemia and lymphoma. The main purpose of this study is to determine if sirolimus can be given safely in combination with standard drugs used to treat relapsed lymphoblastic leukemia/lymphoma.

NCT ID: NCT01657955 Recruiting - Leukemia Clinical Trials

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

CLL
Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT01657682 Completed - Clinical trials for Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This pilot Phase II study is designed to evaluate the efficacy and tolerability of crenolanib in two cohorts of AML patients with FLT3 activation mutations (patients whose leukemia has recurred after prior chemotherapy not including a FLT3 TKI and patients whose leukemia has progressed after prior therapy with a FLT3 TKI).